Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 417 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma June 6, 2025 EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC October 6, 2020 Load more HOT NEWS Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... COVID-19 vaccine and cancer – latest updates How “the most advanced machine learning approach” is finding new cancer-causing...
